Dedicated to transforming the lives of patients with severe and other genetic diseases through innovative gene therapy.
Stem cell technology β’ Gene therapy β’ Orphan diseases β’ Paediatric diseases
201 - 500
π° $150M Post-IPO Equity on 2021-02
2 days ago
201 - 500
Drive payer engagement strategies for Medicaid and government organizations affecting innovative therapies access and reimbursement.
πΊπΈ United States β Remote
π° $150M Post-IPO Equity on 2021-02
β° Full Time
π Senior
π Director
π½ H1B Visa Sponsor